Effect of L-carnitine supplementation on metabolic status,leptin and visfatin adipokines in obese diabetic women with hypocaloric diet

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT138903164105N1

Enrollment

Registered

2011-12-10

Start date

2011-11-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Diabetic. Condition 2: Obesity. Non-insulin-dependent diabetes mellitus obesity

Interventions

Intervention 1: Intervention groups: 1 gr of carnitine tablet twice a day with hypocaloric diet (500 kcal less than patients's energy requirementes ). Intervention 2: Control groups: 1 gr of placebo t

Treatment - Drugs

Placebo

Intervention groups: 1 gr of carnitine tablet twice a day with hypocaloric diet (500 kcal less than patients's energy requirementes )

Control groups: 1 gr of placebo twice a day with hypocaloric diet (500 kcal less than patients's energy requirementes )

Eligibility

Sex/Gender

Female

Age

18 Years to 48 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: obese women with type2 diabetic; age range 18 to 48years; no cancer, liver or renal disease; receiving any therapeutic diet except diabetes diet; no Pregnancy, lactation and menopause of women. Exclusion criteria: Consumption of any food supplement or drug which influence carnitine or lipid profile (such as vitamin B6 - C ); treatment with insulin and Failure to follow the prescribed diet.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Leptin. Timepoint: baseline, endpoint. Method of measurement: Elisa.;Visfatin. Timepoint: baseline, endpoint. Method of measurement: Elisa.;Anthropometric indicators: weight, body mass index, waist circumference, hip circumference and waist to hip ratio. Timepoint: baseline, endpoint. Method of measurement: Standard procedures using scale, tape and equations.;Body Fat Mass. Timepoint: baseline, endpoint. Method of measurement: Bioimpedance.	—

Measure

Time frame

Leptin. Timepoint: baseline, endpoint. Method of measurement: Elisa.;Visfatin. Timepoint: baseline, endpoint. Method of measurement: Elisa.;Anthropometric indicators: weight, body mass index, waist circumference, hip circumference and waist to hip ratio. Timepoint: baseline, endpoint. Method of measurement: Standard procedures using scale, tape and equations.;Body Fat Mass. Timepoint: baseline, endpoint. Method of measurement: Bioimpedance.

—

Secondary

Measure	Time frame
FBS. Timepoint: baseline, endpoint. Method of measurement: autoanalyzer.;Insulin resistance: Insulin, HOMA-IR index. Timepoint: baseline, endpoint. Method of measurement: Elisa and formula.;IL-6, hs-CRP. Timepoint: baseline, endpoint. Method of measurement: Elisa and autoanalyzer.;TG. Timepoint: baseline, endpoint. Method of measurement: autoanalyzer.;Cholesterol. Timepoint: baseline, endpoint. Method of measurement: autoanalyzer.;HDL. Timepoint: baseline, endpoint. Method of measurement: autoanalyzer.;Blood pressure. Timepoint: baseline, endpoint. Method of measurement: sphygmomanometer.	—

Measure

Time frame

FBS. Timepoint: baseline, endpoint. Method of measurement: autoanalyzer.;Insulin resistance: Insulin, HOMA-IR index. Timepoint: baseline, endpoint. Method of measurement: Elisa and formula.;IL-6, hs-CRP. Timepoint: baseline, endpoint. Method of measurement: Elisa and autoanalyzer.;TG. Timepoint: baseline, endpoint. Method of measurement: autoanalyzer.;Cholesterol. Timepoint: baseline, endpoint. Method of measurement: autoanalyzer.;HDL. Timepoint: baseline, endpoint. Method of measurement: autoanalyzer.;Blood pressure. Timepoint: baseline, endpoint. Method of measurement: sphygmomanometer.

—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026